The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Spectrum Pharmaceuticals Inc

  • SPPI
  • NASDAQ
  • Consumer Products
  • Latest 7.05
  • Currency US$
  • Change -0.05
  • Percent Change -0.704 %
  • Volume 655,097
  • Fri Jul 25, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 7.06
  • Previous Close 7.10
  • High 7.16
  • Low 6.95
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High01/23 10.32
  • 52-week Low04/15 6.36
  • Beta 1.352
  • Market Cap 460.29M
  • EPS -1.37
  • P/E
  • Forward P/E 21.36
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $157,310,000
  • Earnings $-85,000,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $117,730,000
  • Current Ratio 2.72

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $474,980,000
  • Liabilities $209,130,000
  • Liabilities-to-Equity Ratio 0.79

Price Ratios

  • Price to Sales 2.93
  • Price to Book 1.73
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 8 $-0.21 Aug 6 $-0.14
Surprises May 8 -104.76% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 28, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and efficacy, and adding value through further clinical development and selection of the most viable and low-risk methods of commercialization. The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as at-home chemotherapy and new treatment regimens for refractory disease.

Related Securities
Symbol Type Latest % Chg

Officers

  • Rajesh C. Shrotriya Chairman of the Board;Chief Ex
  • Kurt A. Gustafson Executive Vice President and C
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

11500 S. EASTERN AVE. SUITE 2
HENDERSON, NV
89052

Phone: (702)-835-6300
Fax: (702)-2607405

ir@sppirx.com
www.sppirx.com

Ideas & Discussion

Live Discussion of SPPI on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.